5-Jul

. 2022 Apr 9;74(7):1191-1198.

doi: 10.1093/cid/ciab611.

Persistent Symptoms in Adult Patients one Year Later on Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Written report

Affiliations

• PMID: 34223884
• PMCID: PMC8394862
• DOI: x.1093/cid/ciab611

Free PMC commodity

Persistent Symptoms in Adult Patients 1 Year Later on Coronavirus Illness 2019 (COVID-nineteen): A Prospective Cohort Written report

Jessica Seeßle  et al. Clin Infect Dis. 2022 .

Free PMC article

Abstract

Background: Long COVID is defined as the persistence of symptoms beyond 3 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To better understand the long-term grade and etiology of symptoms we analyzed a cohort of patients with COVID-19 prospectively.

Methods: Patients were included at 5 months later astute COVID-19 in this prospective, noninterventional, follow-upward study. Patients followed until 12 months after COVID-19 symptom onset (north = 96; 32.3% hospitalized, 55.two% females) were included in this analysis of symptoms, quality of life (based on an SF-12 survey), laboratory parameters including antinuclear antibodies (ANAs), and SARS-CoV-2 antibody levels.

Results: At month 12, only 22.9% of patients were completely free of symptoms and the nearly frequent symptoms were reduced exercise capacity (56.iii%), fatigue (53.1%), dyspnea (37.5%), and problems with concentration (39.vi%), finding words (32.3%), and sleeping (26.0%). Females showed significantly more than neurocognitive symptoms than males. ANA titers were ≥1:160 in 43.6% of patients at 12 months post-COVID-xix symptom onset, and neurocognitive symptom frequency was significantly higher in the group with an ANA titer ≥1:160 versus <1:160. Compared with patients without symptoms, patients with ≥ane long-COVID symptom at 12 months did not differ significantly with respect to their SARS-CoV-2 antibody levels but had a significantly reduced concrete and mental life quality compared with patients without symptoms.

Conclusions: Neurocognitive long-COVID symptoms tin persist ≥1 year after COVID-19 symptom onset and reduce life quality significantly. Several neurocognitive symptoms were associated with ANA titer elevations. This may indicate autoimmunity equally a cofactor in etiology of long COVID.

Keywords: ANA titers; coronavirus illness 2019 (COVID-19); life quality; long COVID.

© The Author(s) 2021. Published past Oxford Academy Press for the Infectious Diseases Gild of America. All rights reserved. For permissions, electronic mail: journals.permissions@oup.com.

Figures

Figure i.

Distribution of ANA titers within study group at acute COVID-19 and five and 12 months post–symptom onset of COVID-19 presented in percent of the total accomplice (n = 96). Abbreviations: ANA, antinuclear antibiotic; COVID-xix, coronavirus disease 2019.

Figure ii.

Frequencies of symptoms (%) in the study accomplice at acute COVID-19, likewise as at v, 9, and 12 months post–COVID-nineteen symptom onset. P values for the grouping differences betwixt v- and 12-month time points are based on McNemar examination for dependent samples. Symptoms with significant differences are marked with an asterisk (*P < .05). Abbreviations: COVID-19, coronavirus disease 2019; n.d., not determined.

Figure 3.

Frequencies of symptoms (%) amid the study population presented every bit a heatmap for the time of acute COVID-nineteen and at 5 and 12 months postal service–symptom onset. Symptom frequencies are stratified past disease severity (mild/moderate and severe/critical illness), gender (male and female), age (<60 and ≥60 years) and ANA titer (<ane:160 vs ≥ 1:160). Gray fields with a cross betoken that this parameter was not analyzed at that specific fourth dimension point. Abbreviations: ANA, antinuclear antibiotic; COVID-19, coronavirus disease 2019.

Figure four.

The PCS and MCS assessed by the SF-12 questionnaire for the report population subgrouped for patients with at least 1 symptom or no symptoms at 12 months mail–COVID-19 symptom onset. Information are presented as medians and interquartile ranges, and P values for the group differences are based on the Isle of mann-Whitney U test for contained samples. Significant differences are marked with an asterisk (*P < .05, **P < .01). Abbreviations: COVID-19, coronavirus disease 2019; MCS, Mental Component Scale; PCS, Physical Component Scale; SF-12, 12-item Short Course Survey.

Like manufactures

• Antibody tests for identification of current and by infection with SARS-CoV-2.

  Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accurateness Grouping. Deeks JJ, et al. Cochrane Database Syst Rev. 2020 Jun 25;vi(six):CD013652. doi: x.1002/14651858.CD013652. Cochrane Database Syst Rev. 2020. PMID: 32584464 Free PMC article.

• Mail-COVID syndrome in not-hospitalised patients with COVID-19: a longitudinal prospective cohort study.

  Augustin Chiliad, Schommers P, Stecher Grand, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L, Roventa M, Riaz T, Tschernoster Northward, Altmueller J, Rose L, Salomon S, Priesner V, Luers JC, Albus C, Rosenkranz Southward, Gathof B, Fätkenheuer G, Hallek Grand, Klein F, Suárez I, Lehmann C. Augustin Yard, et al. Lancet Reg Health Eur. 2021 Jul;half dozen:100122. doi: x.1016/j.lanepe.2021.100122. Epub 2021 May xviii. Lancet Reg Health Eur. 2021. PMID: 34027514 Free PMC article.

• A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.

  Brakenhoff TB, Franks B, Goodale BM, van de Wijgert J, Montes S, Veen D, Fredslund EK, Rispens T, Risch Fifty, Dowling AV, Folarin AA, Bruijning P, Dobson R, Heikamp T, Klaver P, Cronin M, Grobbee DE; COVID-Cherry-red Consortium. Brakenhoff TB, et al. Trials. 2021 Jun 22;22(i):412. doi: x.1186/s13063-021-05241-5. Trials. 2021. PMID: 34158099 Free PMC article.

• Psychiatric and neuropsychiatric presentations associated with astringent coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.

  Rogers JP, Chesney Due east, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis 1000, David Equally. Rogers JP, et al. Lancet Psychiatry. 2020 Jul;7(7):611-627. doi: x.1016/S2215-0366(20)30203-0. Epub 2020 May 18. Lancet Psychiatry. 2020. PMID: 32437679 Free PMC article.

• Post Acute Coronavirus (COVID-19) Syndrome.

  Chippa V, Aleem A, Anjum F. Chippa V, et al. 2022 Feb 6. In: StatPearls [Net]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 Feb six. In: StatPearls [Internet]. Treasure Isle (FL): StatPearls Publishing; 2022 Jan–. PMID: 34033370 Gratis Books & Documents.

Cited by 31 manufactures

• Patient-Reported Symptoms and Sequelae 12 Months After COVID-nineteen in Hospitalized Adults: A Multicenter Long-Term Follow-Up Written report.

  Comelli A, Viero K, Bettini 1000, Nobili A, Tettamanti Thou, Galbussera AA, Muscatello A, Mantero G, Canetta C, Martinelli Boneschi F, Arighi A, Brambilla P, Vecchi One thousand, Lampertico P, Bonfanti P, Contoli M, Blasi F, Gori A, Bandera A. Comelli A, et al. Front end Med (Lausanne). 2022 Mar 22;9:834354. doi: 10.3389/fmed.2022.834354. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35391879 Costless PMC article.

• Long COVID and Symptom Trajectory in a Representative Sample of Americans.

  Wu Q, Ailshire J, Crimmins Due east. Wu Q, et al. Res Sq. 2022 Mar 16:rs.3.rs-1440503. doi: 10.21203/rs.3.rs-1440503/v1. Preprint. Res Sq. 2022. PMID: 35313574 Free PMC article.

• Early clues regarding the pathogenesis of long-COVID.

  Peluso MJ, Deeks SG. Peluso MJ, et al. Trends Immunol. 2022 Apr;43(iv):268-270. doi: 10.1016/j.it.2022.02.008. Epub 2022 Mar 8. Trends Immunol. 2022. PMID: 35272932 Free PMC article.

• Findings From Mayo Clinic's Post-COVID Clinic: PASC Phenotypes Vary by Sexual activity and Degree of IL-vi Peak.

  Durstenfeld MS, Hsue PY, Peluso MJ, Deeks SG. Durstenfeld MS, et al. Mayo Clin Proc. 2022 Mar;97(3):430-432. doi: ten.1016/j.mayocp.2022.01.020. Mayo Clin Proc. 2022. PMID: 35246280 Free PMC article. No abstract bachelor.

• On the single and multiple associations of COVID-19 post-acute sequelae: 6-month prospective cohort study.

  Jiménez-Rodríguez BM, Gutiérrez-Fernández J, Ramos-Urbina EM, Romero-Ortiz Advertisement, García-Flores PI, Santiago-Puertas MI, Martín-López MJ, López-Milena K, Fabregas R, Morales-García C. Jiménez-Rodríguez BM, et al. Sci Rep. 2022 Mar one;12(1):3402. doi: 10.1038/s41598-022-07433-8. Sci Rep. 2022. PMID: 35233062 Complimentary PMC article.

References

1. 1. Prissy COVID-nineteen rapid guidelines. PharmacoEcon Outcomes News 2021;877:33. doi: 10.1007/s40274-021-7682-3. - DOI - PMC - PubMed
2. 1. Nalbandian A, Sehgal Yard, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601–15. doi: 10.1038/s41591-021-01283-z. - DOI - PubMed
3. 1. Dennis A, Wamil M, Alberts J, et al. ; COVERSCAN Study Investigators. Multiorgan impairment in low-chance individuals with post-COVID-19 syndrome: a prospective, community-based report. BMJ Open 2021; eleven:e048391. - PubMed
4. 1. Marx V. Scientists fix out to connect the dots on long COVID. Nat Methods 2021; 18:449–53. - PMC - PubMed
5. 1. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients later acute COVID-19. JAMA 2020; 324:603–5. - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Key
  • Ovid Technologies, Inc.
  • PubMed Cardinal
  • Silverchair Information Systems

• Medical

  • MedlinePlus Wellness Information

• Miscellaneous

  • NCI CPTAC Analysis Portal

pricehateref.blogspot.com

Source: https://pubmed.ncbi.nlm.nih.gov/34223884/

Share this post